Stability and potency of the Plasmodium falciparum MSP1-19/AMA-1(III) chimeric vaccine candidate with Montanide ISA720 adjuvant (Q43144803)

14 November 2017

title

Stability and potency of the Plasmodium falciparum MSP1-19/AMA-1(III) chimeric vaccine candidate with Montanide ISA720 adjuvant (English)

1 reference

14 November 2017

main subject

Plasmodium falciparum

1 reference

Xiangyang Xue

1 reference

14 November 2017

Feng Ding

1 reference

14 November 2017

Qingfeng Zhang

1 reference

14 November 2017

Xuegong Pan

1 reference

14 November 2017

Li Qu

1 reference

14 November 2017

Weiqing Pan

1 reference

14 November 2017

language of work or name

English

0 references

publication date

1 March 2010

1 reference

14 November 2017

1 reference

14 November 2017

1 reference

14 November 2017

1 reference

14 November 2017

page(s)

3152-3158

1 reference

Drug discovery for malaria: a very challenging and timely endeavor

14 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.054

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.054

The global distribution of clinical episodes of Plasmodium falciparum malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.054

Fusion of two malaria vaccine candidate antigens enhances product yield, immunogenicity, and antibody-mediated inhibition of parasite growth in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.054

Pathways and strategies for developing a malaria blood-stage vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.054

Antibodies against merozoite surface protein (MSP)-1(19) are a major component of the invasion-inhibitory response in individuals immune to malaria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.054

Immunization against blood-stage rodent malaria using purified parasite antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.054

Merozoite surface coat precursor protein completely protects Aotus monkeys against Plasmodium falciparum malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.054

Human antibodies to the 19kDa C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 inhibit parasite growth in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.054

Domain III of Plasmodium falciparum apical membrane antigen 1 binds to the erythrocyte membrane protein Kx.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.054

Structure of domain III of the blood-stage malaria vaccine candidate, Plasmodium falciparum apical membrane antigen 1 (AMA1)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.054

Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.054

A phase I clinical trial of a multi-epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.054

Immunogenicity of a recombinant malaria vaccine based on receptor binding domain of Plasmodium falciparum EBA-175.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.054

A human phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in Montanide ISA720 adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.054

Safety and immunogenicity of a malaria vaccine, Plasmodium falciparum AMA-1/MSP-1 chimeric protein formulated in montanide ISA 720 in healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.054

Proteolytic processing of the Plasmodium falciparum merozoite surface protein-1 produces a membrane-bound fragment containing two epidermal growth factor-like domains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.054

The disulfide bond structure of Plasmodium apical membrane antigen-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.054

Montanide ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.054

10.1016/J.VACCINE.2010.02.054

7 January 2021

Identifiers

DOI

1 reference

14 November 2017

1 reference